Cover Image
Market Research Report
Product code 
1058088

Cervical Dysplasia - Market Insight, Epidemiology And Market Forecast - 2030

Published: Pre-Order | DelveInsight Business Research LLP | 113 Pages | Delivery time: 2-10 business days

Price

Back to Top
Cervical Dysplasia - Market Insight, Epidemiology And Market Forecast - 2030
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 113 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's 'Cervical Dysplasia - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Cervical Dysplasia, historical and forecasted epidemiology as well as the Cervical Dysplasia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Cervical Dysplasia market report provides current treatment practices, emerging drugs, Cervical Dysplasia market share of the individual therapies, current and forecasted Cervical Dysplasia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Cervical Dysplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Cervical Dysplasia: Disease Understanding and Treatment Algorithm

Cervical Dysplasia Overview

Cervical dysplasia, also known as cervical intraepithelial neoplasia (CIN), is the abnormal growth of cells on the surface of the cervix or endocervical canal - the opening between the uterus and the vagina. It is usually caused by certain types of human papillomavirus (HPV) and is found when a Pap test or cervical biopsy is done. Depending on how abnormal the cells look under the microscope and how much of the cervical tissue is affected, it can be classified into mild, moderate, or severe. Cervical dysplasia is not cancer but may become cancer and can spread to nearby normal tissue.

The cervix is the lower, narrow end of the uterus that forms a canal between the uterus and vagina. Before cancer cells form in the tissues of the cervix, the cells of the cervix go through abnormal changes called dysplasia. There are different types of dysplasia: mild dysplasia (CIN-1), called low-grade intraepithelial lesion (LSIL); and moderate dysplasia (CIN-2) and severe dysplasia (CIN-3), called high-grade intraepithelial lesion (HSIL). LSIL and HSIL may or may not become cancer. Cervical dysplasia usually causes no symptoms and is most often discovered by a routine Pap test. The prognosis is excellent for women with cervical dysplasia who receive appropriate follow-up and treatment. But women who go undiagnosed or who do not receive appropriate care are at higher risk of developing cervical cancer.

Cervical Dysplasia Diagnosis

All women over the age of 18 who have been sexually active should undergo regular gynecological examinations, including a pelvic exam and Pap test, to detect any abnormal changes to the cervix as soon as possible. Like many other types of cancer, cervical cancer is more likely to be effectively treated if identified early. Inflammation caused by yeast infections, bacterial infections such as trichomonas, gonorrhea, or Chlamydia, other viruses, medicines or other chemicals, hormones, and pregnancy can all be detected with Pap tests.

Cervical cancer screening includes cytology and HPV testing, alone or in combination. Conventional cytology (a Pap test sample affixed to a slide at the time of testing) and liquid-based cytology (a newer method for collecting, transporting, and preparing cells collected by the Pap test in a liquid medium [e.g., ThinPrep Pap test]) provide comparable results. Both methods are acceptable and have nearly equivalent sensitivity and specificity for detecting high-grade CIN.

HPV testing, alone or in combination with cytology, is more sensitive than cytology alone in detecting CIN2 and CIN3. There are a variety of tests approved by the US FDA for detecting cervical HPV, including HPV DNA and HPV mRNA tests. Current methods for using cervical HPV testing in the United States include triage testing for patients with abnormal findings on cytology (reflex testing), adjunct testing with cytology (co-testing), and primary testing.

Cervical Dysplasia Treatment

There are different degrees of dysplasia. Based on the Lower Anogenital Squamous Terminology (LAST) project, pathologists call the specimen low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). LSIL - classically referred to as CIN-1 or mild dysplasia - does not require treatment and is followed conservatively. Patients with LSIL should return in 1 year for co-testing. This involves a repeat Pap smear with HPV molecular testing as most of the lesions will regress on their own. HSIL - classically referred to as CIN-2/3 or CIS - usually requires an excisional procedure for treatment. Ablative procedures can be offered, but most clinicians perform excisional procedures to give the pathologist a better specimen to evaluate. Excisional procedures assure that an underlying cancer is identified and adequate treatment for the lesion is provided.

A loop electrosurgical excision procedure (LEEP) is done to remove the abnormal tissue with a thin electrified wire that cuts the specimen from the cervix can be performed in the office. A cold knife cone (CKC) typically is performed in the operating room, using a knife to resect a cone-shaped portion of cervical tissue. The advantage of a CKC is that the pathologist can identify the margins more clearly and because they are not obscured by the burn artifact created with the electrified wire. Following a complete excision and negative margins, patients require yearly follow-up with a pap smear. If underlying cancer is discovered, treatment plans are expanded, and an oncologist is consulted. If an excisional procedure provides results in positive LEEP margin findings, the decision to re-excise or follow conservatively is based on the patient's age and fertility status.

Cervical Dysplasia Epidemiology

The Cervical Dysplasia epidemiology division provides insights about historical and current Cervical Dysplasia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

As per the DelveInsight estimates, in the year 2020, the total diagnosed incident cases of cervical dysplasia were 2,892,687 cases in the 7MM, which are expected to grow during the study period, i.e.,2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Cervical Dysplasia epidemiology [segmented as Total Diagnosed Incident Cases of Cervical Dysplasia, Total Diagnosed Incident Cases for Cervical Dysplasia by Severity (without year on year impact of vaccination), Total Age group-specific Cases of Cervical Dysplasia (CIN 2+, with impact of HPV vaccination), and Total Treated Cases of Cervical Dysplasia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Cervical Dysplasia Epidemiology

Estimates show that the highest cases of Cervical Dysplasia in the 7MM were in the United States, followed by the France, Germany, Italy, the United Kingdom, Japan, and Spain in 2020.

  • In the year 2020, the total diagnosed incident cases of cervical dysplasia by severity were 2,373,043 (CIN1) and 519,644 (CIN2+) cases in the 7MM, which are expected to grow during the study period, i.e., 2018-2030.
  • The US accounted for 17,894, 91,458, and 85,493 cases for age groups specific cases of CIN 2+ for 18-24 years, 25-34 years, and ≥35 years age group, respectively, in the year 2020, which will probably rise for the age groups 18-24 years, and ≥35 years, respectively, however for the age groups 25-34 years the cases will probably decrease during the study period i.e., 2018-2030.
  • Japan accounted for 2,220, 10,173, and 55,642 treated cases of cervical dysplasia for age groups 18-24 years, 25-34 years, and ≥35 years, respectively, in the year 2020.

Cervical Dysplasia Drug Chapters

The drug chapter segment of the cervical dysplasia report encloses the detailed analysis of cervical dysplasia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the cervical dysplasia is clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Cervical Dysplasia Emerging Drugs

VGX-3100 (Inovio Pharmaceuticals)

VGX-3100 is an investigational immunotherapy vaccine that includes DNA plasmids targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18. VGX-3100 is HPV-specific immunotherapy that is being developed as a nonsurgical treatment for high-grade cervical dysplasia (CIN) and related underlying persistent HPV infection. VGX-3100 works in vivo to activate functional, antigen-specific CD-8 T-cells to clear persistent HPV 16/18 infection and cause regression of precancerous CIN.

IRX-2 (Brooklyn Immuno Therapeutics)

IRX-2 is a mixed, human-derived cytokine product with multiple active constituents, including Interleukin-2, or IL-2, and other key cytokines. Together, these cytokines are believed to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells, unlike existing cancer therapies, which rely on targeting cancer directly. IRX-2 is prepared from the supernatant of pooled allogeneic peripheral blood mononuclear cells, known as PBMNCs, which have been stimulated using a proprietary process employing a specific population of cells and a specific mitogen.

PVX-2 (pNGVL4a-Sig/E7 [Detox]/HSP70) (PapiVax)

PVX-2 is a cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7 (detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immune-stimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8 (+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death.

Artesunate (Frantz Viral Therapeutics)

Artesunate is a semi-synthetic derivative of artemisinin, made by the plant sweet wormwood (Artemisia annua). This Chinese herbal medicine has been used for centuries to treat malaria and now is WHO-approved as a first-line treatment for acute malaria. Its safety profile has been well-documented in treating millions of individuals with acute malaria ranging from infants to adults.

Note: Detailed emerging therapies assessment will be provided in the final report.

Cervical Dysplasia Market Outlook

Cervical dysplasia refers to the presence of precancerous changes of the cells that make up the surface of the cervix, the opening to the womb (uterus). The term dysplasia refers to the abnormal appearance of the cells when viewed under the microscope.

Cervical dysplasia usually causes no symptoms and is most often discovered by a routine Pap test. The prognosis is excellent for women with cervical dysplasia who receive appropriate follow-up and treatment. But women who go undiagnosed or do not receive appropriate care are at higher risk of progressed cervical cancer.

There are different degrees of dysplasia. Based on the Lower Anogenital Squamous Terminology (LAST) project, pathologists call the specimen low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). LSIL, classically referred to as CIN-1 or mild dysplasia, does not require treatment and should be followed conservatively.

Women suffering from low-grade (mild) dysplasia (CIN-1 when the diagnosis is confirmed and all abnormal areas have been visualized) will frequently undergo spontaneous regression of the mild dysplasia without treatment. Treatment is generally appropriate for women who are diagnosed with high-grade cervical dysplasia (CIN-2 and CIN-3). Treatments for cervical dysplasia fall into two general categories: destruction (ablation) of the abnormal area and removal (resection). Both types of treatment are equally effective.

Key Findings

The Cervical Dysplasia market size in the 7MM is expected to change during the study period 2018-2030. The therapeutic market of Cervical Dysplasia in the seven major markets is expected to increase during the study period (2018-2030) with a CAGR of 2.1%. According to the estimates, the highest market size of Cervical Dysplasia is found in the United States followed by Japan.

The United States Market Outlook

The total market size of Cervical Dysplasia therapies in the United States is expected to increase with a CAGR of 2.2% in the study period (2018-2030).

EU-5 Countries: Market Outlook

The total market size of Cervical Dysplasia therapies in EU-5 countries is expected to increase with a CAGR of 1.7% in the study period (2018-2030).

Japan Market Outlook

The total market size of Cervical Dysplasia therapies in Japan is expected to increase with a CAGR of 2.9% in the study period (2018-2030).

Cervical Dysplasia Pipeline Development Activities

The drugs which are in pipeline include:

  • 1. VGX-3100 (Inovio Pharmaceuticals)
  • 2. IRX-2 (Brooklyn Immuno Therapeutics)
  • 3. PVX-2 (pNGVL4a-Sig/E7 [Detox]/HSP70) (PapiVax)
  • 4. Artesunate (Frantz Viral Therapeutics)

Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

Complications associated with the current treatment options and high cost will adversely impact the cervical dysplasia disease market.

Among the emerging therapies, Inovio Pharmaceutical's VGX-3100 and Frantz Viral Therapeutics Artesunate appears to be the only drugs which have the potential to transform the Cervical Dysplasia market owing to impressive clinical data.

Access and Reimbursement Scenario in Cervical Dysplasia Therapies

Health technology assessments (HTAs) evaluate published literature according to evidence-based criteria to present a high-quality scientific synthesis of available evidence regarding clinical benefits, harms, economic consequences, and ethical or social issues. HTAs are increasingly leveraged as an essential requirement for health care decision-making. Ideally, an HTA is expected to evaluate the long-term benefits and risks of a given medical intervention to its costs. Several initiatives have already emerged in the past. However, since no therapy is currently approved for cervical dysplasia, thus no such recommendations have been published. The current treatment is only restricted to LEEP, cryotherapy, and others.

In a study conducted by Henk et al. (2010), to understand the costs of cervical intraepithelial neoplasia (CIN) in the US commercially insured population, it was reported that the treatment costs for an episode of CIN 2, 3 tended to be higher compared with an episode of CIN 1 (USD 1,634 for CIN 2, 3 vs. USD 1,084 for CIN 1). The number of visits for CIN 1 and CIN 2, 3 was similar; CIN 2, 3 visits were likely more intensive, treatment-focused than CIN 1. Specifically, these visits may involve the use of more expensive procedures such as conization, loop electrosurgical excision procedures, and occasionally hysterectomy, which are more commonly used in the treatment of CIN 2, 3 compared with CIN 1. The population burden per 1,000 women was greater for CIN 2, 3 (USD 1,803) compared with CIN 1 (USD 1,059). The highest costs for CIN 1 were found among women between 21 and 30 years old (USD 3,417) and for those between 31 and 40 years old (USD 3,760). The burden of CIN 2, 3 was also highest among these age groups (USD 7,303 and USD 3,007, respectively).

Note: Detailed HTA assessment will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Cervical Dysplasia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cervical Dysplasia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cervical Dysplasia Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Cervical Dysplasia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Cervical Dysplasia epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cervical Dysplasia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Cervical Dysplasia market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cervical Dysplasia market.

Report Highlights:

  • In the coming years, the Cervical Dysplasia market is set to change due to the upcoming therapies with novel mechanism of action which are under investigation and ongoing research in the Cervical Dysplasia; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cervical Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Cervical Dysplasia. The launch of emerging therapies will significantly impact the Cervical Dysplasia market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cervical Dysplasia.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cervical Dysplasia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cervical Dysplasia Pipeline Analysis
  • Cervical Dysplasia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cervical Dysplasia Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Cervical Dysplasia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cervical Dysplasia Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Cervical Dysplasia Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Cervical Dysplasia total market size as well as market size by therapies across the 7MM during the study period (2018-2030)?
  • What are the key findings of the market across the 7MM and which country will have the largest Cervical Dysplasia market size during the study period (2018-2030)?
  • At what CAGR, the Cervical Dysplasia market is expected to grow in the 7MM during the study period (2018-2030)?
  • What would be the Cervical Dysplasia market outlook across the 7MM during the study period (2018-2030)?
  • What would be the Cervical Dysplasia market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Cervical Dysplasia patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Cervical Dysplasia market?

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of the Cervical Dysplasia?
  • What is the historical Cervical Dysplasia patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Cervical Dysplasia in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Cervical Dysplasia?
  • Out of all the 7MM countries, which country would have the highest diagnosed incident population of Cervical Dysplasia during the study period (2018-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Cervical Dysplasia?

    Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Cervical Dysplasia?
  • What are the current treatment guidelines for the treatment of Cervical Dysplasia in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Cervical Dysplasia?
  • How many therapies are developed by each company for the treatment of Cervical Dysplasia?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Cervical Dysplasia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cervical Dysplasia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cervical Dysplasia and their status?
  • What are the key designations that have been granted for the emerging therapies for Cervical Dysplasia?
  • What is the global historical and forecasted market of Cervical Dysplasia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Cervical Dysplasia market.
  • To understand the future market competition in the Cervical Dysplasia market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Cervical Dysplasia in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Cervical Dysplasia market.
  • To understand the future market competition in the Cervical Dysplasia market.
Product Code: DIMI1358

Table of Contents

1. Key Insights

2. Report Introduction

3. Cervical Dysplasia Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Cervical Dysplasia in 2018
  • 3.2. Market Share (%) Distribution of Cervical Dysplasia in 2030

4. Executive Summary of Cervical Dysplasia

  • 4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Classification of Cervical Intraepithelial Neoplasia
  • 6.3. Causes and Risk Factors
  • 6.4. Sign and Symptoms
  • 6.5. Pathophysiology of Cervical Dysplasia
  • 6.6. Biomarkers of Cervical Dysplasia
    • 6.6.1. HPV DNA
    • 6.6.2. HPV Viral load
    • 6.6.3. HPV mRNA
    • 6.6.4. HPV L1 Capsid protein
  • 6.7. Complications

7. Diagnosis of Cervical Dysplasia

  • 7.1. Diagnostic Algorithm of Cervical Dysplasia
  • 7.2. Cytology-based screening
  • 7.3. Visual inspection with acetic acid (VIA)
  • 7.4. Colposcopy
  • 7.5. Human Papillomavirus DNA Test

8. Prevention

  • 8.1. Gardasil 9
  • 8.2. Gardasil
  • 8.3. Cervarix

9. Treatment of Cervical Dysplasia

  • 9.1. Cryotherapy
  • 9.2. Laser Treatment
  • 9.3. Conization
  • 9.4. Loop electrosurgical excision procedure (LEEP)
  • 9.5. Hysterectomy

10. Diagnosis and Treatment Guideline for Cervical Dysplasia

  • 10.1. WHO Guideline for Screening and Treatment of Cervical Precancer Lesions for Cervical Cancer prevention
  • 10.2. American Society for Colposcopy and Cervical Pathology (ACCSP) Guidelines for Risk-based Management Consensus for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

11. Epidemiology and Patient Population

  • 11.1. Key Findings
  • 11.2. Epidemiology of Cervical Dysplasia
  • 11.3. Epidemiology Scenario
    • 11.3.1. Total Diagnosed Incident Cases of Cervical Dysplasia
    • 11.3.2. Total Diagnosed Incident Cases for Cervical Dysplasia by Severity (without year on year impact of vaccination)
    • 11.3.3. Total Age group-specific Cases of Cervical Dysplasia (CIN 2+, with impact of HPV vaccination)
    • 11.3.4. Total Treated Cases of Cervical Dysplasia

12. Patient Journey

13. Key Endpoints in Cervical Dysplasia Clinical Trials

14. Emerging Therapies

  • 14.1. VGX-3100: Inovio Pharmaceuticals
    • 14.1.1. Product Description
    • 14.1.2. Other Development Activities
    • 14.1.3. Clinical Developmental Activities
    • 14.1.4. Safety and Efficacy
  • 14.2. IRX-2: Brooklyn Immuno Therapeutics
    • 14.2.1. Product Description
    • 14.2.2. Other Developmental Activities
    • 14.2.3. Clinical Developmental Activities
  • 14.3. PVX-2 (pNGVL4a-Sig/E7 [Detox]/HSP70): PapiVax
    • 14.3.1. Product Description
    • 14.3.2. Clinical Developmental Activities
  • 14.4. Artesunate: Frantz Viral Therapeutics
    • 14.4.1. Product Description
    • 14.4.2. Clinical Developmental Activities
    • 14.4.3. Safety and Efficacy

15. Cervical Dysplasia: 7 Major Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Outlook
  • 15.3. Market Size of Cervical Dysplasia
    • 15.3.1. Total Market Size of Cervical Dysplasia
    • 15.3.2. Market Size of Cervical Dysplasia by Therapies

16. Market Access and Reimbursement

  • 16.1. Future Therapy Assessment

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

  • 22.1. Bibliography
  • 22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Tables

  • Table 1: Summary of Cervical dysplasia, Market, Epidemiology, and Key Events (2018-2030)
  • Table 2: Vaccination and screening rate in the 7MM
  • Table 3: Total Diagnosed Incident Cases of Cervical Dysplasia in the 7MM (2018-2030)
  • Table 4: Total Diagnosed Incident Cases for Cervical Dysplasia by Severity (without year on year impact of vaccination) in the 7MM (2018-2030)
  • Table 5: Total Age group-specific Cases of Cervical Dysplasia (CIN 2+, with impact of HPV vaccination) in the 7MM (2018-2030)
  • Table 6: Total Treated Cases of Cervical Dysplasia in the 7MM (2018-2030)
  • Table 7: VGX-3100, Clinical Trial Description, 2021
  • Table 8: IRX-2, Clinical Trial Description, 2021
  • Table 9: PVX-2, Clinical Trial Description, 2021
  • Table 10: Artesunate, Clinical Trial Description, 2021
  • Table 11:7MM Market Size of Cervical Dysplasia in USD Million (2018-2030)
  • Table 12: 7MM Market Size of Cervical Dysplasia by Therapies in USD Million (2018-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Understanding of Cervical Dysplasia
  • Figure 3: Classification of Cervical Intraepithelial Neoplasia
  • Figure 4: Causes and Risk Factors of Cervical Dysplasia
  • Figure 5: Sign and Symptoms of Cervical Dysplasia
  • Figure 6: Pathophysiology of Cervical Dysplasia
  • Figure 7: Diagnosis of Cervical Dysplasia
  • Figure 8: Pap Smear Test
  • Figure 9: Colposcopy
  • Figure 10: Loop Electrosurgical Excision Procedure
  • Figure 11: Total Diagnosed Incident of Cervical Dysplasia in the 7MM (2018-2030)
  • Figure 12: Total Diagnosed Incident Cases for Cervical Dysplasia by Severity (without year on year impact of vaccination) in the 7MM (2018-2030)
  • Figure 13: Total Age group-specific Cases of Cervical Dysplasia (CIN 2+, with impact of HPV vaccination) in the 7MM (2018-2030)
  • Figure 14: Total Treated Cases of Cervical Dysplasia in the 7MM (2018-2030)
  • Figure 15: Market Size of Cervical Dysplasia in the 7MM, USD Million (2018-2030)
  • Figure 16:7MM Market Size of Cervical Dysplasia by Therapies in USD Million (2018-2030)